Early Optimization of Ceftazidime Regimen in Critical Care

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how to give the antibiotic ceftazidime in the best way for patients in the intensive care unit (ICU) who have serious infections like sepsis or infections caused by the bacteria Pseudomonas aeruginosa. Because these patients can have very different kidney function and other body changes, a standard dose of the antibiotic may not always work well—some may get too little or too much medicine. The trial aims to find a more personalized way to give the right dose by adjusting it based on how each patient’s body handles the drug.

Patients who might take part are adults in the ICU expected to stay at least three days and who need ceftazidime treatment for infection. They must have a special catheter in an artery to allow easy blood sampling and be covered by social security. Pregnant women, those without consent, or people with very poor kidney function are not eligible. Participants will receive either the usual dosing method or a new, tailored dosing plan developed through the study, and their responses to treatment will be carefully monitored to see which approach works best. This research could help doctors give antibiotics more safely and effectively to very sick patients in the future.

Gender

ALL

Eligibility criteria

• Inclusionn criteria:
• • Patient hospitalized in intensive care unit for an expected duration of at least 72 hours, with an infection for which initiation of ceftazidime therapy is being considered.
• • Patient with an arterial catheter for blood sampling.
• • Patients affiliated to or entitled under a social security scheme.
• Exclusion Criteria:
• • Pregnant woman, parturient, nursing mother;
• • Person deprived of liberty, hospitalized without consent,
• • Adults under legal protection (guardianship-curatorship)
• • Patients undergoing extra-renal purification or whose CKD-EPI at the start of treatment is less than 15 ml/min.